Asthma Therapeutics in Major Developed Market Size & Share to 2020

1
Asthma Therapeutics in Major Developed Markets to
2020 - Personalized Treatment for Severe Asthma
to Drive Market Growth despite Patent Expirations
No. Pages 142
Published on February - 2015
2
.
Report Overview
About Asthma Therapeutics in Major Developed
Markets to 2020 Research Beam added a report
Asthma Therapeutics in Major Developed Markets
to 2020 - Personalized Treatment for Severe
Asthma to Drive Market Growth despite Patent
Expirations. Summary GBI Research, a leading
business intelligence provider, has released its
latest research report, Asthma Therapeutics in
Major Developed Markets to 2020 - Personalized
Treatment for Severe Asthma to Drive Market
Growth despite Patent Expirations. The asthma
therapeutics market is forecast to grow
marginally over the forecast period across the
top eight developed nations, from 18.4 billion
in 2013 to a projected value of 21.7 billion by
2020 at a Compound Annual Growth Rate (CAGR) of
2.4. This is in spite of generic erosion facing
several of the leading asthma brands, such as
Advair (fluticasone propionate/salmeterol
xinafoate), Symbicort (budesonide/formoterol
fumarate) and Xolair (omalizumab), and is a
consequence of new market entrants and rising
disease prevalence. Get Full Details On
http//www.researchbeam.com/asthma-therapeutics-in
-major-developed-to-2020-personalized-treatment-fo
r-severe-asthma-to-drive-growth-despite-patent-exp
irations-market
3
.
Report Overview
The global prevalence of asthma is significant,
believed to affect approximately 300 million
people worldwide. This burden is predicted to
increase in future, reaching 400 million by
2025.   Although the majority of asthma patients
are able to manage their symptoms effectively
using currently marketed products, some remain
inadequately controlled with these same products.
This unmet need, coupled with rising global
prevalence, has resulted in strong industry
interest.   Consequently, the current asthma
pipeline is highly innovative, featuring several
promising molecules in late-stage drug
development. Biologics and monoclonal antibodies,
the latter in particular, are gaining prominence
within the indication. Novel monoclonal
antibodies such as mepolizumab, reslizumab,
lebrikizumab, and dupilumab target Interleukins
(IL), or IL receptors, and have demonstrated
potential in severe and inadequately controlled
eosinophilic asthma, in turn representing a shift
towards personalized therapy. Despite the fact
that they target only a small patient sub-set,
they are likely to be priced highly and to drive
market growth, offsetting the impact of generic
erosion.
4
.
Report Overview

• Scope
• The report covers and includes -
• - An introduction to asthma, including discussion
  of disease epidemiology, etiology
  pathophysiology, symptoms, diagnosis, and
  treatment, with clinical data for drugs featured
  in the current treatment algorithm discussed in
  detail
• - In-depth analysis of the current marketed
  products landscape, including product profiles of
  the main drugs used and heat maps that compare
  their safety and efficacy parameters
• - Comprehensive analysis of the asthma pipeline
  by phase of development, molecule type, and
  molecular target and novelty, and comparative
  analysis of the most promising late-stage
  pipeline drugs, as well as heat maps and a
  competitor matrix that compares safety and
  efficacy parameters
• - Additional in-depth analysis of the asthma
  clinical trials landscape, including trends in
  size, duration and failure rate
• - Forecast projections for the asthma market to
  2020, including analysis of the global market and
  each of the eight major markets and incorporating
  projected, low, and high-variance scenarios based
  on
•  

5
Report Overview

• treatment usage patterns and annual cost of
  therapy in each of the major markets
• Discussion of the strategic consolidations
  landscape, including trends in co-development and
  licensing deals relevant to asthma drug products
• Reasons to buy
•  
• The report will assist business development and
  enable marketing executives to strategize their
  product launches by allowing them to -
• - Gain a comprehensive understanding of asthma,
  including diagnosis, disease severity, and
  treatment algorithms
• - Understand the current asthma marketed products
  landscape and recognize the dominant therapeutic
  agents and pharmaceutical players involved
• - Identify trends, developments, and prominent
  molecule types and molecular targets within the
  asthma pipeline
•  

6
Report Overview

• - Gain an appreciation of the clinical and
  commercial aspects of the most promising
  late-stage pipeline molecules and their potential
  competitive impact on the future market
• - Consider market opportunities and potential
  risks by examining trends in asthma clinical
  trial size, duration and failure rate, phase of
  development, molecule type, and molecular target
• - Observe projections for treatment usage
  patterns, annual therapy costs, and market growth
  in the eight major markets and understand reasons
  for variance in projected patterns of growth
•  

7
Table Of Contents
1 Table of Contents 51.1 List of Tables 71.2
List of Figures 82 Introduction 102.1 Disease
Introduction 102.2 Epidemiology 102.3 Etiology
112.4 Pathophysiology 122.5 Symptoms 122.6
Diagnosis 122.7 Assessment of Disease Severity
132.8 Treatment 152.9 Treatment Algorithm 16
8
Table Of Contents
2.10 Treatment Segments 182.10.1 ICS Monotherapy
for the Maintenance Treatment of Asthma 192.10.2
Singulair (montelukast sodium) as First-Line
Maintenance Therapy 212.10.3 ICS/LABA
Combination Therapy 222.10.4 Add-on Therapies
273 Marketed Products 333.1 Overview 333.2 ICS
for the Maintenance Treatment of Asthma 333.2.1
Arnuity (fluticasone furoate) - GSK 333.3
ICS/LABA Combination Therapy for the Maintenance
Treatment of Asthma 343.3.1 Advair (fluticasone
propionate and salmeterol xinafoate) - GSK
34Enquiry about this report _at_ http//www.research
beam.com/asthma-therapeutics-in-major-developed-to
-2020-personalized-treatment-for-severe-asthma-to-
drive-growth-despite-patent-expirations-market/enq
uire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/asthma-therapeutics-in
-major-developed-to-2020-personalized-treatment-fo
r-severe-asthma-to-drive-growth-despite-patent-exp
irations-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com